Supplementary Table S3 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
crossref（2024）
摘要
Table S3 shows incidence of new peripheral neuropathy over time in patients receiving combination treatment in EV-103
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要